Juventas Therapeutics

Focused on cell therapy

Gene and Cell Therapy
Beijing, Tianjin, Shanghai, China

About the company

Clinical stage company focused on cell therapy with pipeline in hematologic malignancies, solid tumors, and auto-immune diseases. The lead asset is CNCT19, an autologous anti-CD19 CAR-T that is the first CAR-T cell therapy for treatment of B-ALL and has the potential to be the first domestically developed CD19-directed CAR-T therapy specifically approved for B-ALL in China. The drug has obtained a total of 3 INDs from the NMPA. Juventas has partnered with CASI pharmaceutical for global co-commercialization of CNCT19. The company has an extensive pipeline of 10 product candidates with targets such as CD19/CD22, BCMA and EGFR TGF-βKO.